TABLE 1.

Summary of Features in Selected Clinical Trials on OMPC

Trial	Imaging modality	Oligometastatic definition	Oligometastatic therapy	Outcome measure	Reference
ORIOLE	CT, BS	≤3 bone or LN	SABR vs. observation	Progression at 6 m	54
POPSTAR	¹⁸F-NaF PET/CT	≤3 bone	SABR	Radiographic PFS	55
RAVENS	CT, BS	≤3 bone or ST (at least 1 bone)	SABR + ²²³RaCl₂	PFS	56
STOMP	Choline PET/CT	≤3 bone or LN	Surveillance vs. SABR	ADT-free survival	61
LOCATE	¹⁸F-fluciclovine PET/CT	≤5 extraprostatic (≤3 in any single organ)	NA	Change in management	64
TROD 09-004	PSMA PET/CT	≤5 bone	SABR	2-y PFS	73
OLI-P	PSMA PET/CT	≤5 bone or LN	SABR	Time to ADT initiation; time to PSA progression	75
BULLSEYE	PSMA PET/CT	≤5 bone or LN	¹⁷⁷Lu-PSMA-617 vs. SOC (deferred ADT)	Progression at 24 wk	78

BS = bone scan; LN = lymph node; NA = not applicable; SOC = standard of care; ST = soft tissue.